A Study about Blood Pressure Management in Patients with Primary Aldosteronism

Official Title
A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Effectiveness of CIN-107 for the Management of Blood Pressure in Patients with Primary Aldosteronism

The purpose of this study is to see how the study drug CIN-107 works in managing blood pressure in patients with primary aldosteronism (PA), a hormone disorder which causes your body to produce too much of the hormone aldosterone.

The duration of this study is 74 weeks. 

Could this study be right for you?
  • Diagnosis of primary aldosteronism (PA)
  • Taking an MRA to control BP, such as Spironolactone or Eplerenone, or not yet taking an MRA
Age Range
18 and up